From NAFLD to MASLD: transforming steatotic liver disease diagnosis and management

Abstract

The transition from non-alcoholic fatty liver disease (NAFLD) to metabolic dysfunction-associated steatotic liver disease (MASLD) represents a significant evolution in the nomenclature of steatotic liver disease. This updated terminology emphasizes metabolic dysfunction as a central criterion, offering greater precision and improved risk stratification. MASLD broadens the scope of liver disease classification by incorporating individuals with diverse metabolic profiles, including lean patients with hepatic steatosis, and aligns clinical practice with the multifactorial nature of this condition. The global adoption of MASLD creates opportunities for standardization in clinical and research settings, facilitating multicenter collaborations and enhancing the development of diagnostic tools and therapeutic strategies. However, the adoption of this new nomenclature poses challenges, including potential confusion during implementation, cultural and linguistic barriers, the integration of MetALD, and the need for educational initiatives targeting healthcare providers and patients. Further efforts are required to refine diagnostic criteria, address implementation challenges, and seamlessly incorporate MASLD into international coding systems. This review evaluates the key advantages and ongoing challenges associated with MASLD, providing a comprehensive analysis of its impact on clinical practice, research, and global health strategies.

Keywords

NAFLD / MAFLD / MASLD / steatotic liver disease / MetALD

References

[1] Addison T. Observations on fatty degeneration of the liver. Guys Hosp Rep. 1836;1:476-85. Available from https://catalog.hathitrust.org/Record/010088303 [Last accessed on 5 Mar 2025].

[2] Ludwig J,McGill DB.Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease.Mayo Clin Proc1980;55:434-8

[3] Younossi ZM,Paik JM,Van Dongen C.The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review.Hepatology2023;77:1335-47 PMCID:PMC10026948

[4] Byrne CD.NAFLD: a multisystem disease.J Hepatol2015;62:S47-64

[5] Genua I,Rodríguez-Duque JC,Crespo J.NAFLD and type 2 diabetes: a practical guide for the joint management.Gastroenterol Hepatol2023;46:815-25

[6] Eslam M, Sanyal AJ, George J; International Consensus Panel. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999-2014.e1.

[7] Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J Hepatol. 2023;79:1542-56.

[8] Younossi ZM,Abdelatif D,Henry L.Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology2016;64:73-84

[9] Hong S,Hao Y.From NAFLD to MASLD: when metabolic comorbidity matters.Ann Hepatol2024;29:101281

[10] McPherson S,Henderson E,Day CP.Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management.J Hepatol2015;62:1148-55

[11] Shang Y,Modica A.Metabolic syndrome traits increase the risk of major adverse liver outcomes in type 2 diabetes.Diabetes Care2024;47:978-85 PMCID:PMC11116921

[12] Song R,Zhang Y,Chen Z.Comparison of NAFLD, MAFLD and MASLD characteristics and mortality outcomes in United States adults.Liver Int2024;44:1051-60

[13] Ormazabal V,Elfeky O,Salomon C.Association between insulin resistance and the development of cardiovascular disease.Cardiovasc Diabetol2018;17:122 PMCID:PMC6119242

[14] Wu SH,Ho SC.Metabolic syndrome and all-cause mortality: a meta-analysis of prospective cohort studies.Eur J Epidemiol2010;25:375-84

[15] Lombardi R,Targher G.Liver fibrosis by FibroScan^® independently of established cardiovascular risk parameters associates with macrovascular and microvascular complications in patients with type 2 diabetes.Liver Int2020;40:347-54

[16] Li G,Chen Z,Liu D.Bidirectional association between hypertension and NAFLD: a systematic review and meta-analysis of observational studies.Int J Endocrinol2022;2022:8463640 PMCID:PMC8970889

[17] Siddiqui MS,Idowu MO.Severity of nonalcoholic fatty liver disease and progression to cirrhosis are associated with atherogenic lipoprotein profile.Clin Gastroenterol Hepatol2015;13:1000-8.e3 PMCID:PMC4395517

[18] Huxley R,Zheleznyakov E,Chan J.Body mass index, waist circumference and waist:hip ratio as predictors of cardiovascular risk--a review of the literature.Eur J Clin Nutr2010;64:16-22

[19] De A,Mehta M,Duseja A.Metabolic dysfunction-associated steatotic liver disease (MASLD) definition is better than MAFLD criteria for lean patients with NAFLD.J Hepatol2024;80:e61-2

[20] Hutchison AL,Romeo S.Endocrine aspects of metabolic dysfunction-associated steatotic liver disease (MASLD): beyond insulin resistance.J Hepatol2023;79:1524-41

[21] Duseja A,Wong V.Special population: lean nonalcoholic fatty liver disease.Clin Liver Dis2023;27:451-69

[22] Alboraie M,Piscoya A.Why MASLD lags behind MAFLD: a critical analysis of diagnostic criteria evolution in metabolic dysfunction-associated liver diseases.Med Sci Monit2024;30:e945198 PMCID:PMC11299466

[23] Park H,Kim M,Nah EH.Nomenclature dilemma of metabolic associated fatty liver disease (MAFLD): considerable proportions of MAFLD are metabolic healthy.Clin Gastroenterol Hepatol2023;21:1041-9.e3

[24] Huang J,Wang M,Lin S.MAFLD criteria overlooks a number of patients with severe steatosis: is it clinically relevant?.J Hepatol2020;73:1265-7

[25] Meroni M,Paolini E.MAFLD definition underestimates the risk to develop HCC in genetically predisposed patients.J Intern Med2022;291:374-6

[26] Sookoian S,Valenti L.Genetics of metabolic dysfunction-associated steatotic liver disease: the state of the art update.Clin Gastroenterol Hepatol2024;22:2177-87.e3 PMCID:PMC11512675

[27] Thakral N,Diaz LA.A precision medicine guided approach to the utilization of biomarkers in MASLD.Semin Liver Dis2024;44:273-86

[28] Bugianesi E,Marchesini G.Insulin resistance: a metabolic pathway to chronic liver disease.Hepatology2005;42:987-1000

[29] Liebe R,Bock HH.Diagnosis and management of secondary causes of steatohepatitis.J Hepatol2021;74:1455-71

[30] Staufer K,Strebinger G.Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease.J Hepatol2022;77:918-30

[31] Bataller R,Shah VH.Alcohol-associated hepatitis.N Engl J Med2022;387:2436-48

[32] Marti-Aguado D,Vilar-Gomez E.Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease.J Hepatol2024;81:930-40

[33] Whitfield JB, Schwantes-An TH, Darlay R, et al; GenomALC Consortium. A genetic risk score and diabetes predict development of alcohol-related cirrhosis in drinkers. J Hepatol. 2022;76:275-82. PMCID:PMC8803006

[34] Burton R,Sharpe C.The independent and joint risks of alcohol consumption, smoking, and excess weight on morbidity and mortality: a systematic review and meta-analysis exploring synergistic associations.Public Health2024;226:39-52

[35] Scott E.Genetics of alcoholic liver disease and non-alcoholic steatohepatitis.Clin Med2018;18:s54-9 PMCID:PMC6334028

[36] Nasr P,Ekstedt M.Misclassified alcohol-related liver disease is common in presumed metabolic dysfunction-associated steatotic liver disease and highly increases risk for future cirrhosis.Clin Gastroenterol Hepatol2024;22:1048-57.e2

[37] Targher G,Tilg H.MASLD: a systemic metabolic disorder with cardiovascular and malignant complications.Gut2024;73:691-702

[38] Cheng YM,Kao JH.Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.Hepatol Int2023;17:350-6

[39] Santos-Laso A,Alonso-Peña M.Pathophysiological mechanisms in non-alcoholic fatty liver disease: from drivers to targets.Biomedicines2021;10:46 PMCID:PMC8773141

[40] Tilg H.The role of cytokines in non-alcoholic fatty liver disease.Dig Dis2010;28:179-85

[41] De Filippo O,Nebiolo M.Increased prevalence of high-risk coronary plaques in metabolic dysfunction associated steatotic liver disease patients: a meta-analysis.Eur J Clin Invest2024;54:e14188

[42] Solomon A,Cipăian CR.Interactions between metabolic syndrome, MASLD, and arterial stiffening: a single-center cross-sectional study.Healthcare2023;11:2696 PMCID:PMC10572783

[43] Kang MK,Loomba R.Comparative associations of MASLD and MAFLD with the presence and severity of coronary artery calcification.Sci Rep2024;14:22917 PMCID:PMC11447001

[44] Pan Z,Esmat G,Eslam M.MAFLD predicts cardiovascular disease risk better than MASLD.Liver Int2024;44:1567-74

[45] Ciardullo S.The MAFLD-MASLD debate: does cardiovascular risk prediction define the winner?.Liver Int2024;44:1564-6

[46] Ciardullo S,Morieri ML,Invernizzi P.Impact of MASLD and MetALD on clinical outcomes: a meta-analysis of preliminary evidence.Liver Int2024;44:1762-7

[47] Loomba R.Implications of the new nomenclature of steatotic liver disease and definition of metabolic dysfunction-associated steatotic liver disease.Aliment Pharmacol Ther2024;59:150-6 PMCID:PMC10807722

[48] Chrysavgis L.From NAFLD to MASLD: what does it mean?.Expert Rev Gastroenterol Hepatol2024;18:217-21

[49] Sanyal AJ,Wong VW.Noninvasive assessment of liver fibrosis in NAFLD.Clin Gastroenterol Hepatol2023;21:2026-39

[50] Wong VWS,Cusi K.Management of NAFLD in primary care settings.Liver Int2022;42:2377-89

[51] Eskridge W,Schattenberg JM.Metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: the patient and physician perspective.J Clin Med2023;12:6216 PMCID:PMC10573476

[52] Lee CM,Kim M.Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings.Hepatology2024;79:1393-400

[53] Iruzubieta P,Arias-Loste MT,Crespo J.Evaluation of metabolic dysfunction-associated steatotic liver disease (MASLD) terminology in different clinical settings.J Hepatol2024;80:e121-3

[54] Song SJ,Wong GL,Yip TC.Can we use old NAFLD data under the new MASLD definition?.J Hepatol2024;80:e54-6

[55] European Association for the Study of the Liver (EASL); European Association for the Study of Diabetes (EASD); European Association for the Study of Obesity (EASO). EASL-EASD-EASO clinical practice guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD). J Hepatol. 2024;81:492-542. PMCID:PMC11299976

[56] Lazarus JV, Mark HE, Allen AM, et al; Healthy Livers, Healthy Lives Collaborators. A global action agenda for turning the tide on fatty liver disease. Hepatology. 2024;79:502-23. PMCID:PMC10789386

[57] Hagström H,Allen AM.The future of international classification of diseases coding in steatotic liver disease: an expert panel Delphi consensus statement.Hepatol Commun2024;8:e0386 PMCID:PMC10843430

[58] Arab JP,Rehm J.Metabolic dysfunction and alcohol-related liver disease (MetALD): position statement by an expert panel on alcohol-related liver disease.J Hepatol2024;Epub ahead of print:

[59] Rinella ME, Lazarus JV, Ratziu V, et al; NAFLD Nomenclature consensus group. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. Hepatology. 2023;78:1966-86. PMCID:PMC10653297

[60] Puhl RM.Weight stigma and barriers to effective obesity care.Gastroenterol Clin North Am2023;52:417-28

[61] Lazarus JV,Palayew A.A Twitter discourse analysis of negative feelings and stigma related to NAFLD, NASH and obesity.Liver Int2021;41:2295-307

[62] Carol M, Pérez-Guasch M, Solà E, et al; LiverHope Consortium Investigators. Stigmatization is common in patients with non-alcoholic fatty liver disease and correlates with quality of life. PLoS One. 2022;17:e0265153. PMCID:PMC8986095

[63] Younossi ZM, Alqahtani SA, Alswat K, et al; Global NASH Council. Global survey of stigma among physicians and patients with nonalcoholic fatty liver disease. J Hepatol. 2024;80:419-30.

[64] Younossi ZM, AlQahtani SA, Funuyet-Salas J, et al; Global NASH Council. The impact of stigma on quality of life and liver disease burden among patients with nonalcoholic fatty liver disease. JHEP Rep. 2024;6:101066. PMCID:PMC11252535

[65] Méndez-Sánchez N,Fassio E,Prado-Robles JA.MAFLD: perceived stigma-a single-center Mexican patient survey.Hepatol Int2023;17:507-8

[66] Shiha G,Casanovas T.MAFLD 2022: An ELPA/ALPA/EASO-ECPO joint statement on disease stigma.J Hepatol2022;77:1717-9

[67] Ramírez-Mejía MM,Abenavoli L.The myth of the stigma of fatty liver: what does the evidence show?.Ann Hepatol2024;29:101535

[68] Mendez-Sanchez N,Gadano A.The Latin American Association for the Study of the Liver (ALEH) position statement on the redefinition of fatty liver disease.Lancet Gastroenterol Hepatol2021;6:65-72

[69] Sun M,Yao VJH.Screening for social determinants of health in underserved populations to promote better outcomes in ALD and MASLD.Clin Gastroenterol Hepatol2025;23:379-80

[70] Kim RG,Conroy MB,Inadomi JM.Screening for social determinants of health among populations at risk for MASLD: a scoping review.Front Public Health2024;12:1332870 PMCID:PMC11041393

[71] Lazarus JV, Mark HE, Anstee QM, et al; NAFLD Consensus Consortium. Advancing the global public health agenda for NAFLD: a consensus statement. Nat Rev Gastroenterol Hepatol. 2022;19:60-78.

[72] Lazarus J V,Villota-Rivas M.The global NAFLD policy review and preparedness index: are countries ready to address this silent public health challenge?.J Hepatol2022;76:771-80

[73] Alboraie M,Eslam M.Letter to the editor: MAFLD versus MASLD-which is more appropriate from a global perspective?.Hepatology2024;80:E42-3

[74] Hoofnagle JH.Letter to the editor: a multi-society Delphi consensus statement on new fatty liver disease nomenclature.Hepatology2024;79:E91-2

[75] Fouad Y,El-Shabrawi M.Letter to the editor: how F to S turned the premature to be mature?.Hepatology2024;79:E157-8

[76] Emanuele E.Letter to the editor: NAFLD, MAFLD or MASLD?.Hepatology2024;79:E4

[77] Alboraie M,Xu X.Global multi-societies endorsement of the MAFLD definition.Ann Hepatol2024;29:101573

[78] Targher G,Byrne CD.Non-alcoholic fatty liver disease: a multisystem disease requiring a multidisciplinary and holistic approach.Lancet Gastroenterol Hepatol2021;6:578-88